Diabetic and non-diabetic patients have similar in-hospital mortality rates. Survival rates of diabetic patients start to deteriorate 3 year after surgery. Type 2 DM is an independent predictor for long-term mortality after isolated CABG surgery. Mortality is even higher when the diabetes treatment strategy included insulin (Cardiovascular Diabetology)
Diabetes News
Category: Cardiovascular
Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?
We propose the introduction of UDCI as a standardised terminology, and call for a concerted effort to increase awareness of this condition and its consequences. By so doing, it should be possible to define the correct screening programme to facilitate early and appropriate treatment of patients with T2D and to minimise adverse CV outcomes (Cardiovascular Diabetology)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
Among adults with type 2 diabetes and high CV and renal risk, linagliptin added to usual care compared with placebo added to usual care resulted in a noninferior risk of a composite CV outcome over a median 2.2 years (JAMA)
Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial)
Renal biomarkers informing various aspects of kidney function may further our understanding of the complex interplay between diabetic kidney disease and cardiovascular disease (American Journal of Cardiology)
The association between diabetes mellitus and reduction in myocardial glucose uptake: a population-based 18F-FDG PET/CT study
Diabetes is associated with decreased myocardial glucose metabolism, which is mediated by multiple metabolic abnormalities (BMC Cardiovascular Disorders)
Role of Tight Glycemic Control during Acute Coronary Syndrome on CV Outcome in Type 2 Diabetes
In conclusion, optimal glucose target levels and treatment regimens in this setting of patients are still under debate. Future studies on intensive glucose control must be developed to reduce both glucose variability and risk of hypoglycemia, thus achieving an optimal blood glucose concentration in critically ill patients, particularly in ACS (Journal of Diabetes Research)
Early vascular parameters in the micro- and macrocirculation in type 2 diabetes
These data suggest that at similar blood pressure capillary rarefaction in the retinal circulation (ICD), decreased eGFR in the renal circulation and increased central pulse pressure (cPP) of large arteries are earlier detectable than other vascular remodeling parameters of the micro- (WLR, RCF, UACR) and macrocirculation (cSBP) in patients with T2DM (Cardiovascular Diabetology)
Increased Residual Cardiovascular Risk in Patients with Diabetes and High vs. Normal Triglycerides Despite Statin‐Controlled LDL Cholesterol
Despite statin‐controlled LDL‐C levels, CV events were greater among patients with diabetes and high TG levels. Because we controlled for cardiometabolic risk factors, it is likely that the difference in TG levels contributed to the excess risk observed in patients with high TGs (Diabetes, Obesity and Metabolism)
Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study
The development of T2D in an incident population of PsA is significantly higher than in psoriasis alone or in a general population, whereas the increased risk of cardiovascular disease in PsA and psoriasis is similar (Rheumatology)
Ethnicity-specific association of BMI levels at diagnosis of type 2 diabetes with cardiovascular disease and all-cause mortality risk
This study suggests a paradoxical association of BMI with cardiovascular and mortality risks in different ethnic groups, which may partially be driven by different cardiovascular and glycaemic risk profiles at diagnosis (Acta Diabetologica)
The relationship between urinary albumin excretion, cardiovascular outcomes and total mortality among a large cohort of insulin-treated patients with type 2 diabetes in routine primary care practices
This study shows that in patients with T2D on insulin therapy, increased urinary ACR is independently associated with an increased risk of major adverse CV events and all-cause mortality (Nephrology Dialysis Transplantation)
Cardiovascular Outcomes of Sodium Glucose Cotransporter‐2 Inhibitors in Patients with Type 2 Diabetes
Using population‐based data, incident use of SGLT‐2 inhibitors was associated with a decreased incidence of CVD compared to sulfonylurea and DPP‐4 inhibitors. These findings were consistent between dapagliflozin and canagliflozin suggesting that CVD reduction is a class effect for SGLT2 inhibitors (Diabetes, Obesity and Metabolism)
Dissimilar impact of type 2 diabetes on cardiovascular outcomes according to age categories: a nationwide population study from Hungary
The risk of cardiovascular outcomes and all-cause mortality is significantly higher in patients with T2DM. Notably, the relative hazard increases with decreasing age suggesting that younger patients with T2DM should receive more attention for cardiovascular prevention (Cardiovascular Diabetology)
Impact of acute diabetes decompensation on outcomes of diabetic patients admitted with ST-elevation myocardial infarction
Decompensated diabetes complicates ~ 1.5% of STEMI admissions in diabetic patients. It is associated with lower rates of referral for angiography and revascularization, and a negative differential impact on in-hospital morbidity and mortality and cost (Diabetology & Metabolic Syndrome)
Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus
Our findings suggest that SGLT-2i reduced hHF compared with DPP-4i. A heart failure protective effect of SGLT-2i use vs. DPP-4i use was shown 30 days after initiating the SGLT-2i among patients with established CVD, but this effect appeared later in patients without established CVD (Cardiovascular Diabetology)
SGLT-2 Inhibitors and Cardiovascular Risk
In this large, multinational, observational study, initiation of SGLT-2i was associated with lower risk of death and HF regardless of pre-existing CVD. Ongoing clinical trials will provide further evidence regarding the benefit of SGLT-2i in patients without established CVD (Journal of the American College of Cardiology)
Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure
The beneficial effects of SGLT2 inhibitors on such outcomes and the heart itself are unique characteristics among antidiabetic agents, and SGLT2 inhibitors are expected to be a promising therapeutic option for CV disease and HF care (Cardiovascular Diabetology)
Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year
A continuous care treatment including nutritional ketosis in patients with T2D improved most biomarkers of CVD risk after 1 year. The increase in LDL-cholesterol appeared limited to the large LDL subfraction. LDL particle size increased, total LDL-P and ApoB were unchanged, and inflammation and blood pressure decreased (Cardiovascular Diabetology)
Bone markers and cardiovascular risk in type 2 diabetes patients
Higher osteopontin concentrations were associated with an increased CVD risk in type 2 diabetes patients. No consistent associations were found for the other five bone markers and risk of CVD in type 2 diabetes patients (Cardiovascular Diabetology)
Exercise capacity in diabetes mellitus is predicted by activity status and cardiac size rather than cardiac function
Exercise capacity is reduced in T2DM subjects relative to matched controls, whereas exercise capacity is preserved in T1DM. There was no evidence of sub-clinical cardiac dysfunction but, rather, there was an association between impaired exercise capacity, small LV volumes and sedentary behavior (Cardiovascular Diabetology)
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 12
- Next Page »
Glycosmedia is also available as an App: